These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 146730)

  • 1. Fibrinolytic enzyme in the lining walls of chronic subdural hematoma.
    Ito H; Komai T; Yamamoto S
    J Neurosurg; 1978 Feb; 48(2):197-200. PubMed ID: 146730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Plasminogen activation and regulation of fibrinolysis].
    Madoiwa S
    Nihon Rinsho; 2014 Jul; 72(7):1218-23. PubMed ID: 25163311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical localization of tissue-type plasminogen activator in the lining wall of chronic subdural hematoma.
    Fujisawa H; Ito H; Saito K; Ikeda K; Nitta H; Yamashita J
    Surg Neurol; 1991 Jun; 35(6):441-5. PubMed ID: 1905064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of local hyperfibrinolysis in the etiology of chronic subdural hematoma.
    Ito H; Yamamoto S; Komai T; Mizukoshi H
    J Neurosurg; 1976 Jul; 45(1):26-31. PubMed ID: 132513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extrinsic plasminogen activator: a new principle in fibrinolysis.
    Lijnen HR
    Behring Inst Mitt; 1983 Aug; (73):43-55. PubMed ID: 6236789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Fluctuations in pulmonary fibrin decomposing activities (plasmin and non-plasmin activities) in an endotoxin DIC model in rats].
    Okamoto U; Sasaki K; Nagao N; Naiki I; Nagamatsu Y
    Nihon Seirigaku Zasshi; 1982; 44(11):633-41. PubMed ID: 6221092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
    Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
    J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Significance of the factors in wound healing for the origin of chronic subdural hematoma--fibronectin and its related substances].
    Nishida S
    No To Shinkei; 1992 Jun; 44(6):565-70. PubMed ID: 1389564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy.
    Collen D; Lijnen HR
    Thromb Haemost; 1995 Jul; 74(1):167-71. PubMed ID: 8578451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrinolytic activity in periodontal disease. The relationship between fibrinolytic activity and severity of periodontal disease.
    Hidaka N; Maeda K; Kawakami C; Aono M; Okada H
    J Periodontol; 1981 Apr; 52(4):181-6. PubMed ID: 6453215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrinolysis and thrombosis of fibrinogen-modified gold nanoparticles for detection of fibrinolytic-related proteins.
    Jian JW; Chiu WC; Chang HT; Hsu PH; Huang CC
    Anal Chim Acta; 2013 Apr; 774():67-72. PubMed ID: 23567118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro comparison of fibrinolytic activity of plasminogen activators using a thrombelastographic method: in vivo evaluation of the B-chain-streptokinase complex in the dog model using pre-titered doses.
    Summaria L; Sandesara J; Yang G; Vagher JP; Caprini JA
    Thromb Haemost; 1986 Aug; 56(1):71-9. PubMed ID: 2946093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The role of tissue plasminogen activator in chronic subdural hematomas].
    Mochizuki R
    No To Shinkei; 1987 Oct; 39(10):947-52. PubMed ID: 3124875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Inhibition of esterase by L-lysine, the activator and fibrinolytic activity of the plasmin-streptokinase activator complex].
    Aĭsina RB; Gaĭsarian ES; Snitko IaE; Varfolomeev SD
    Bioorg Khim; 1994 Feb; 20(2):182-9. PubMed ID: 8155080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
    Wu JH; Diamond SL
    Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrinolysis--a review.
    Kane KK
    Ann Clin Lab Sci; 1984; 14(6):443-9. PubMed ID: 6239587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
    Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
    Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The behavior of alpha2-plasmin inhibitor in fibrinolytic states.
    Aoki N; Moroi M; Matsuda M; Tachiya K
    J Clin Invest; 1977 Aug; 60(2):361-9. PubMed ID: 68962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Localization of fibrinolytic activity and inhibition of plasmin in the spinal cord of rat, guinea pig, and rabbit.
    Smokovitis A; Astrup T
    J Neurosurg; 1978 Jun; 48(6):1008-14. PubMed ID: 149186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasmin-alpha 2-plasmin inhibitor complex and alpha 2-plasmin inhibitor in chronic subdural hematoma.
    Saito K; Ito H; Hasegawa T; Yamamoto S
    J Neurosurg; 1989 Jan; 70(1):68-72. PubMed ID: 2521247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.